Approval adds to the growing portfolio of AtriCure products now
available in the Japanese market
MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016--
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it has received approval from the Japanese Ministry of Health, Labor and
Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation probe.
The approval marks the first time that these products will be available
in the Japanese market.
“We are pleased to have this approval in hand, and to be able to bring
our cryoablation products to the Japanese market,” said Mike Carrel,
President and CEO of AtriCure. “This new approval will augment our
offerings in the Japanese market and offer a leading solution to cardiac
surgeons and the Japanese patients for the treatment of Afib.”
The company’s distributor in Japan, Century Medical Inc. (CMI), worked
closely with AtriCure to secure approval. Product will be immediately
available for sale as soon as the reimbursement application is
completed, which is expected in the fourth quarter.
“Japanese surgeons have been waiting a long time for this moment. We
believe many patients will benefit from this technology and look forward
to bringing it to market,” said Takahiko Motani, president and CEO of
AtriCure, Inc. is a medical device company that provides innovative
solutions designed to decrease the global Afib epidemic. AtriCure’s
Isolator® Synergy™ Ablation System is the first and only surgical device
approved for the treatment of persistent and longstanding persistent
forms of Afib in patients undergoing certain open concomitant
procedures. AtriCure’s AtriClip® Left Atrial Appendage Management (LAAM)
exclusion device is the most widely sold device worldwide that is
indicated for the occlusion of the left atrial appendage. AtriCure
believes electrophysiologists and cardiothoracic surgeons are adopting
its technologies for the treatment of Afib and reduction of Afib related
complications. Afib affects more than 33 million people worldwide. For
more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005161/en/
Source: AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Director, Corporate Marketing and Communications
Senior Vice President
and Chief Financial Officer